Association Between Janus Kinase Inhibitors Therapy and Mental Health Outcome in Rheumatoid Arthritis: A Systematic Review and Meta-analysis

Ghazala M. H. Shamail · Madhumitha Haridoss · Meenakumari Natarajan · Vasna Joshua · Bhavani Shankara Bagepally

Received: October 4, 2021 / Accepted: November 24, 2021 / Published online: December 13, 2021
© The Author(s) 2021

ABSTRACT

Introduction: Rheumatoid arthritis (RA) is a chronic debilitating illness, usually associated with mental health ailments. Literature reports contradictory observations about the association between recent RA pharmacotherapies and mental health. We systematically reviewed RA randomized control trials to synthesize the association between Janus kinases (JAK) inhibitors therapy and mental health.

Methods: We systematically searched clinical trials of JAK inhibitor intervention reporting mental health outcomes using short form-36 (SF-36) in PubMed, Embase, and Scopus databases from inception to February 2021. We have selected the studies and extracted the data, adhering to Preferred Reporting Items of Systematic reviews and Meta-Analysis (PRISMA) guidelines. We have pooled the mean change of SF-36 mental component score (MCS) between JAK inhibitors and comparator therapy with a 95% confidence interval.

Results: Of the 2915 searched studies for systematic review, 19 studies involving 14,323 individuals were included for the meta-analysis. The pooled mean reduction in SF-36 MCS scores (after minus before) with JAK inhibitors was 4.95 (4.41–5.48). The pooled mean difference of incremental mean change in SF-36 MCS score between JAK monotherapy and comparator was 1.53 (0.88–2.18). The improvement in SF-36 MCS scores with JAK inhibitor therapy is greater than the minimum clinically important difference (MCID) value of 2.5. However, on separate analysis with comparator drugs like methotrexate and standard treatment, the MCS scores did not exceed the MCID value and were also not statistically significant.

Conclusions: JAK inhibitors results in clinically meaningful improvement in the mental health scores of the RA patients.

PROSPERO Registration ID: 2021CRD42021234466.

Keywords: Rheumatoid arthritis; Janus kinase inhibitors; Tofacitinib; Baricitinib; Upadacitinib; Filgotinib; Mental health; Short form-36
**INTRODUCTION**

Rheumatoid arthritis (RA) is an autoimmune disease prevalent in 0.5–1.0% of individuals, which affects joints [1]. Functional ability is highly compromised in RA patients, causing a substantial impact on both physical and mental quality of life. Literature suggests that about 17% of RA patients suffer from depression, and 25.1% show signs of anxiety [2]. Poor mental health is linked to various detrimental outcomes in RA, including an increased risk of death [3], severe disease activity [4], impaired physical function, increased pain [5], work inability, and fatigue [6]. According to a 2013 systematic review, the pooled depression estimates derived from gold-standard clinical interviews indicate that severe depression affects 16.8% of RA patients [7]. Therefore, mental health is an important component of clinical trial assessment in RA.

Patient-reported outcomes such as short form-36 (SF-36), EuroQol’s five dimensional questionnaire [EQ-5D], Health Assessment Questionnaire are often used to assess the health status of individuals and to study the effect of RA treatments in clinical trials [8]. SF-36 is a validated health-related quality of life (HRQOL) instrument used in a broad spectrum of medical conditions to measure the patient’s physical and mental health status as well as the quality of life (QoL) [9]. According to recent research, RA treatment may help RA patients with high levels of inflammation improve their mental health [10]. This could be associated with increased levels of inflammatory markers in depressed individuals [11]. Therefore, it is speculated that targeting inflammatory molecules could be beneficial in improving mental health symptoms. In the last two decades, RA treatment has evolved with newer biologic and targeted therapies which specifically inhibit the inflammatory cytokines [tumor necrosis factor (TNF-α), interleukin-6 (IL-6)], and small molecules [Janus kinase (JAK)] respectively [12]. Existing evidence suggests that TNF-α and IL-6 inhibitors reduce depression/improves mental health in people with chronic physical illness [13, 14]. It is also observed that antidepressants that regulate the JAK pathway may be beneficial in decreasing RA peripheral inflammation, according to preliminary findings [15–17]. Therefore, JAK inhibitors might have the potential to mitigate the depression observed in RA patients thereby improving their mental health. Several RA clinical trials with JAK inhibitors have reported patient-reported outcomes (particularly SF-36) [18–35] however were inconclusive about its benefit on mental health. Therefore, we aimed to determine the effect of JAK inhibitors on the mental health of RA patients by systematic review and meta-analysis of SF-36 mental component score (MCS).

**METHODS**

We conducted a systematic review and meta-analysis adhering to the guidelines of PRISMA [36], and the protocol was registered in PROSPERO (Prospero 2021 ID: CRD42021234466). This article is based on previously conducted studies and does not contain any new studies
with human participants or animals performed
by any of the authors.

**Screening and Study Selection**

Clinical trials of JAK inhibitors reporting the mental health of RA patients assessed using SF-36 were systematically searched in PubMed, Embase, and Scopus using search terms from inception until February 2021. The PIOUS approach, i.e., population (RA), intervention (JAK inhibitors-tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib), outcome (SF-36), and study design (clinical trial) was employed to construct the search terms. The details of the search strategy are provided in Supplementary Tables 1, 2, and 3. In line with the objectives, studies that reported SF-36 MCS scores among adult RA individuals treated with JAK inhibitors were included. Studies involving other arthritis, such as juvenile idiopathic arthritis or psoriatic arthritis, were excluded. Letter to editors, case reports, conference abstracts, observational studies, reviews, in vitro studies/pre-clinical studies was exempted from the review. The titles and abstracts of the studies were independently screened by two reviewers (GS and BSB) using the Rayyan-web app for systematic reviews after removing the duplicates [37]. Later full texts of studies were screened based on selection criteria, and the final list of selected studies was prepared on authors’ mutual consensus (GS, BSB, and MK) (Fig. 1).

**Data Extraction and Management**

From the selected studies, relevant details were extracted using a data extraction form created in Microsoft Excel v.2016. The data extraction form recorded participant details and characteristics, including mean age, gender (%), RA diagnosis criteria, and SF-36 scores. The SF-36 consists of eight domains, including four scales for the physical health measure comprising physical functioning (ten items), role-physical (four items), bodily pain (two items), and general health (five items) and four scales for the mental health measure composed of vitality (four items), social functioning (two items), role-emotional (three items), and mental health (five items) [9]. The sum of all domains with different weights provides two summary scores, a physical component score (PCS) and a mental component score (MCS). Higher scores indicate better health status. We extracted and used the MCS component scores.

Additionally, the data extraction sheet also recorded author names, study title, year of publication, follow-up period, sample size, intervention, comparator, the country where the study was conducted, trial name, and phase of the clinical trial. Data on central tendency (mean/median) and dispersion [standard deviation (SD)/standard error (SE)/interquartile range (IQR)/95% confidence interval (CI)] were extracted from the included studies by GS, verified independently by MH and finalized on mutual consensus(GS, BSB, and MH).

**Assessment of Risk of Bias**

We assessed the risk of bias (ROB) using a revised Cochrane risk of bias tool for randomized trial (RoB-2 tool) [38]. ROB-2 assesses the ROB in randomized control trials (RCTs) in the five domains, including randomization process, deviation from intended intervention, missing outcome data, measurement of outcome, and selection of reported results. Two authors (MH and MK) independently assessed the quality of included studies, and disagreements were resolved by consensus.

**Statistical Analysis**

Two approaches were used to determine the effect of JAK inhibitors on mental health. The first approach, the incremental mean change of SF-36 MCS scores, was estimated as the difference between SF-36 MCS scores between baseline and last follow-ups for each of the studies. The incremental mean changes of SF-36 MCS scores were then pooled across all the studies to estimate the change/improvement in mental health scores with the JAK inhibitor treatment. In the second approach, we have calculated the mean difference (MD) between the SF-36 MCS scores.
scores’ incremental mean change of JAK inhibitors therapy with that of other DMARDs/placebo. This MD was pooled across all the studies to provide the relative change or improvement with the JAK inhibitors compared to other DMARDs/placebo. In both approaches, the respective effect measures were pooled along with their 95% CI. The random-effects model with the Hedge’s method was used if heterogeneity was present; otherwise, a fixed-effect model was employed for pooling.

Heterogeneity was assessed using visual inspection of forest plots, Cochran’s Q test, and $I^2$ statistics. $I^2$ describes the percentage of the variability in effect estimates due to heterogeneity rather than sampling error (chance); the $I^2$ value of $\geq 40\%$ was considered as presence of substantial heterogeneity [39]. Cochran’s Q is the weighted sum of squared differences between individual study effects and the pooled effect across studies, with the weights being those used in the pooling method. Q is a Chi-square statistic with $k$ (number of studies) minus one degree of freedom. If the $Q(k-1)$ value is greater than the tabulated value (obtained using degrees of freedom) and the $p$ value is $< 0.1$ then heterogeneity is considered to be present [40].

Subgroup/sensitivity analysis was performed to investigate the influence of follow-up duration, phases of the clinical trial, and comparator drugs on heterogeneity. However, it was conducted only if sufficient (at least $\geq 2$) studies were available for each subgroup. The sensitivity analysis was conducted by pooling incremental mean change of SF-36 MCS score for JAK inhibitors and comparator to know individual drug effects on the mental health outcome. Data were recorded using Microsoft Excel v.2016, and analysis was performed using Stata version 16 [41]. All results were considered statistically significant at $p < 0.05$, except for the subgroup analysis and heterogeneity test, wherein $p < 0.10$ was regarded as significant.
Further, the SF-36 MCS scores greater than 2.5 MCID was considered to indicate clinically significant improvement in mental health [42]. Meta-regression was performed with SF-36 PCS to see if improvement in SF-36 MCS is affected by PCS. Publication bias was assessed using a funnel plot (asymmetry) and Egger’s test \( p < 0.05 \) [43], only if sufficient (at least ten) number of studies were available for pooling. Further, on identifying asymmetry in the funnel plot, the source of asymmetry was explored using a contour-enhanced funnel plot.

**RESULTS**

**Description of Studies**

The electronic search retrieved 2915 articles. After removing duplicates and screening titles and abstracts, 548 full texts were screened. Full-text scrutiny resulted in the selection of 19 studies involving 14,323 individuals for the final synthesis [18–35, 44]. The PRISMA flowchart shows the selection of studies (Fig. 1).

The characteristics of these 19 included studies are described in Table 1. The trial participants’ mean age was 52.8 years and were predominantly (81.9%) females. The sample size in individual studies ranged from 136 to 1593 participants. The interventions reported were tofacitinib, baricitinib, upadacitinib, and filgotinib either as monotherapy or combination with methotrexate (MTX) in 11, four, three, and one studies, respectively. Because none of the peficitinib studies reported SF-36, it was excluded from this review. The comparator was either placebo, MTX, or placebo plus MTX or adalimumab (TNF-\( \alpha \) inhibitor). Fifteen studies were conducted in phase 3, and four studies were conducted in phase 2 of the clinical trial. All the included studies have assessed the efficacy of the JAK inhibitor, except one study, which has assessed the monthly medical expenditure and job loss [44]. Two studies [19, 22] (10.5%) were conducted in European countries, and the United States of America, two studies [26, 27] (10.5%) were conducted in Japan, one study [31] (5%) in China, and the remaining 14 studies (73.6%) were conducted all over the world. In six out of 19 studies [18, 19, 27, 29, 30, 32], American College of Rheumatology (ACR) 1987 criteria were used for RA diagnosis, and in two studies [18, 23] 2010 ACR/EULAR was used. The diagnostic criteria were not stated in other studies. The follow-up duration for these studies ranged from 6 to 284 weeks. ROB assessment showed a low ROB for all the studies included (Supplementary Fig. 1).

**Results of Pooling**

Pooled incremental mean change in SF-36 MCS score with JAK monotherapy from 17 studies was 4.95 (4.41–5.48, \( I^2 = 77.09\% \)) with high heterogeneity (Fig. 2). The SF-36 MCS scores greater than 2.5 (MCID) indicate significant improvement in RA patients’ mental health following JAK monotherapy. The test of \( h \), with \( p < 0.1 \), indicates that pooled results are statistically significant. Funnel plot shows symmetry suggesting no publication bias (Supplementary Fig. 2).

Subgroup analysis based on follow-up durations (<24 and ≥24 weeks) and phases of clinical trials (phase 2 and phase 3) showed similar results (Supplementary Figs. 3, 4). However, high heterogeneity (<24 weeks, \( I^2 = 77.38\% \); ≥24 weeks \( I^2 = 78.77\% \)) was observed in both the subgroups, which could not explain the cause for overall heterogeneity (Supplementary Fig. 3). Similarly, subgroup analysis based on the phases of clinical trials (phase 2 and phase 3) also showed similar results with high heterogeneity (phase 2, \( I^2 = 63.78\% \); phase 3, \( I^2 = 79.07\% \)) in the subgroups (Supplementary Fig. 4). RA patients included in this meta-analysis either had inadequate response to MTX alone, csDMARDs alone, bDMARDs alone or both csDMARDs and bDMARDs. We performed a subgroup analysis to observe if the incremental change in SF-36 MCS differ based on their prior treatment responses and could be contributing to the heterogeneity (Supplementary Fig. 5). Among the subgroups, RA patients who had an inadequate response to MTX alone showed a pooled incremental mean change of 5.19 and the
| Author          | Year | Trial name | Country                                                                 | Sample size | Mean age (years) | Female (%) | Duration (in weeks) | Intervention                                      | Comparator              |
|-----------------|------|------------|-------------------------------------------------------------------------|-------------|------------------|------------|---------------------|---------------------------------------------------|-------------------------|
| Coombs et al.   | 2009 | NCT00147498 | Belgium, Brazil, Canada, Germany, Italy, Mexico, Spain, USA              | 264         | 50.6             | 85.6       | 6                   | Tofacitinib (5 mg, 15 mg, 30 mg BID)               | Placebo                 |
| Emery et al.    | 2017 | RA-BUILD   | Argentina, Australia, Belgium, Canada, Croatia, Czechia, Germany, Hungary, Italy, Japan, Korea, Mexico, Russia, Slovakia, Spain, Taiwan, UK, USA | 684         | 51.8             | 81.9       | 24                  | Baricitinib (2 mg, 4 mg) QD + csDMARD             | Placebo + csDMARD       |
| Genovese et al. | 2018 | DARWIN-1 DARWIN-2 | Argentina, Australia, Austria, Belgium, Bulgaria, Chile, Colombia, Israel, Latvia, Mexico, Moldova, New Zealand, Poland, Russian Federation, Spain, Ukraine, USA | 877         | 52.75            | 81.3       | 24                  | MTX + filgotinib (50 mg, 100 mg, 200 mg) MTX + placebo, placebo | MTX + placebo           |
|                 |      |            |                                                                         |             |                  |            |                     | MTX + filgotinib (25 mg, 50 mg, 100 mg) BID       | MTX + placebo           |
|                 |      |            |                                                                         |             |                  |            |                     | Filgotinib (50 mg, 100 mg, 200 mg) QD             | MTX + placebo           |
| Keystone et al. | 2017 | RA-BEAM    | Argentina, Belgium, Canada, China, Croatia, Czechia, France, Germany, Slovakia, Slovenia, South Africa, Spain, Switzerland, Taiwan, UK, USA | 1305        | 53.3             | 77.2       | 52                  | MTX + baricitinib (2 mg, 4 mg) ID                 | Placebo + MTX, adalimumab + MTX |
| Li et al. [31]  | 2018 | ORAL Sync  | China                                                                   | 792         | 52.3             | 81.4       | 52                  | MTX + tofacitinib (5 mg) BID tofacitinib (10 mg) BID | Placebo advanced to intervention at third month |
| Author Year | Trial name | Country | Sample size | Mean age (years) | Female (%) | Duration (in weeks) | Intervention | Comparator |
|-------------|------------|---------|-------------|------------------|------------|---------------------|--------------|------------|
| Rendas-Baum et al. [44] | 2017 ORAL-Step ORAL-standard | Australia, Austria, Belgium, Brazil, Canada, Puerto Rico, Spain, Taiwan, USA | 1116 | 53.95 | 82.85 | 24 | MTX | ?
| | | | | | | | | tofacitinib (5 mg, 10 mg) BID |
| | | | | | | | | Tofacitinib (5 mg, 10 mg) BID |
| Schiff et al. [27] | 2017 RA-BEGIN | Argentina, Austria, Belgium, Brazil, Canada, Germany, Greece, India, Italy, Japan, Korea, Mexico, South Africa, Sweden, UK, USA | 584 | 49.9 | 72.8 | 52 | Baricitinib 4 mg | MTX |
| Smolen et al. [26] | 2016 RA-BEACON | Argentina, Australia, Austria, Belgium, Canada, Denmark, France, Germany, Greece, Israel, Italy, Japan, Korea, Mexico, Netherlands, Poland, Puerto Rico, Spain, Switzerland, Turkey, UK, USA | 527 | 55.7 | 81.7 | 24 | Baricitinib (2 mg, 4 mg) | Placebo |
| Strand et al. [32] | 2014 NCT00961440 | Australia, Austria, Belgium, Brazil, Canada, France, Germany, Ireland, Italy, Korea, Puerto Rico, Spain, Taiwan, USA | 399 | 55 | 84 | 24 | MTX | Placebo advanced to intervention at third month |

Table 1 continued |
| Author          | Year | Trial name         | Country                                                                                           | Sample size | Mean age (years) | Female (%) | Duration (in weeks) | Intervention | Comparator                  |
|-----------------|------|--------------------|---------------------------------------------------------------------------------------------------|-------------|------------------|------------|---------------------|--------------|-----------------------------|
| Strand et al.   | 2015 | NCT00814307        | Brazil, Bulgaria, Chile, Colombia, Czech Republic, Dominican Republic, Germany, India, Malaysia, Mexico, Philippines, Poland, Puerto Rico, Russian Federation, Ukraine, USA | 611         | 51.8             | 86.6       | 24                  | Tofacitinib (5 mg, 10 mg) BID | Placebo, placebo + tofacitinib (5 mg) BID |
| Strand et al.   | 2016 | ORAL START TRIAL   | Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Costa Rica, Czechia, Dominican Republic, Germany, Hungary, India, Korea, Malaysia, Mexico, New Zealand, Sweden, Taiwan, Thailand, Ukraine, USA | 956         | 49.6             | 79.3       | 108                 | Tofacitinib (5 mg, 10 mg) BID | MTX |
| Strand et al.   | 2019 | ORAL strategy      | Argentina, Australia, Bosnia and Herzegovina, Bulgaria, Canada, Chile, Czechia, Estonia, Israel, Korea, Latvia, Lithuania, Mexico, Peru, Philippines, Spain, Taiwan, Thailand, Turkey, UK, USA | 1146        | 50.1             | 82.9       | 52                  | Tofacitinib 5 mg BID tofacitinib 5 mg BID + MTX | ADA + MTX |
| Author       | Year | Trial name                  | Country                                                                 | Sample size | Mean age (years) | Female (%) | Duration (in weeks) | Intervention                  | Comparator |
|--------------|------|-----------------------------|-------------------------------------------------------------------------|-------------|------------------|------------|---------------------|-------------------------------|------------|
| Strand et al. | 2019 | SELECT-NEXT                | Argentina, Australia, Austria, Belgium, Bosnia, Bulgaria, Canada, Mexico, New Zealand, Poland, Portugal, Puerto Rico, Romania, Russia, Slovakia, South Africa, Spain, Switzerland, Taiwan, Turkey, Ukraine, UK, USA | 661         | 55.7             | 78.7       | 12                  | Upadacitinib (15 mg, 30 mg)  | Placebo    |
| Strand et al. | 2019 | SELECT-BEYOND              | Australia, Austria, Belgium, Canada, Czechia, Estonia, Finland, France, Germany, Poland, Portugal, Puerto Rico, Russian Federation, Slovakia, Spain, Sweden, Switzerland, Turkey, UK, USA | 498         | 57.1             | 83.9       | 12                  | Upadacitinib (15 mg, 30 mg)  | Placebo    |
| Strand et al. | 2020 | SELECT-EARLY, SELECT-MONOTHERY | Argentina, Australia, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Puerto Rico, Romania, Russian Federation, Serbia, Slovakia, Slovenia, South Africa, Spain, Switzerland, Taiwan, Tunisia, Turkey, Ukraine, UK, USA | 1593        | 54               | 78.2       | 12                  | Upadacitinib (15 mg, 30 mg)  | Placebo    |
| Author         | Year | Trial name        | Country                                                                 | Sample size | Mean age (years) | Female (%) | Duration (in weeks) | Intervention                        | Comparator                                                                 |
|----------------|------|-------------------|-------------------------------------------------------------------------|-------------|------------------|------------|---------------------|-------------------------------------|----------------------------------------------------------------------------|
| Strand et al.  | 2020 | ORAL Scan         | Australia, Brazil, Bulgaria, Canada, Colombia, Czech Republic, Greece, India, Japan, Korea, Mexico, Poland, Taiwan, Ukraine, USA | 797         | 52.8             | 85.2       | 108                 | MTX + tofacitinib (5 mg, 10 mg) BID | Placebo advanced to intervention at third month                          |
| Tanaka         | 2011 | NCT00603512      | Japan                                                                   | 136         | 51.3             | 86         | 12                  | Tofacitinib (1 mg, 3 mg, 5 mg, 10 mg) BID | Placebo                                                                     |
| Wallenstein    | 2016 | CONSORT (Comb)    | Argentina, Brazil, Bulgaria, Chile, Czech Republic, Hungary, Mexico, Poland, Slovakia, Spain, Sweden, Turkey, USA | 891         | 53.3             | 83.4       | 24                  | Tofacitinib (1 mg, 3 mg, 5 mg, 10 mg, 15 mg, 20 mg) QD + MTX | Placebo, adalimumab 40 mg QOW                                               |
| Yamanaka et al. | 2016 | A3921041         | Japan                                                                   | 486         | 52.6             | 83.1       | 284                 | Tofacitinib 5 mg BID                     | Tofacitinib 10 mg BID                                                  |

QD once a day, BID twice a day, MTX methotrexate, SF-36 MCS score short form-36 mental component summary score, csDMARDs conventional synthetic disease-modifying antirheumatic drugs
heterogeneity decreased to 23.28% in the subgroup. RA patients who showed inadequate response to MTX/TNF-α showed the highest incremental mean change of 7.05 (reported in one study only) followed by 6.27 incremental mean change in treatment naïve patients.

Sensitivity analysis was performed by separately pooling the effect measure for baricitinib, tofacitinib, and upadacitinib to assess the effect of individual JAK inhibitors on mental health (Supplementary Figs. 5, 6, 7). Pooled incremental mean change of SF-36 MCS scores are greater than 2.5 for all the drugs, with highest for tofacitinib [5.32 (4.62–6.03, $I^2 = 67.83\%$)] (Supplementary Fig. 6), followed by upadacitinib [4.68 (3.89–5.47, $I^2 = 70.59\%$)] (Supplementary Fig. 7) and baricitinib [3.93 (2.24–5.62, $I^2 = 80.44\%$)] (Supplementary Fig. 8). Only one study involving filgotinib reported mental health outcomes measured using SF-36 in RA patients. Hence separate analysis could not be performed for filgotinib. However, the individual study of filgotinib showed an incremental mean change of 5.4 in the SF-36 MCS, which is greater than the MCID value of 2.5, indicating clinically meaningful improvement in mental health.

Pooled mean difference of incremental mean change in SF-36 MCS score between JAK inhibitors and other therapies was 1.53 (0.88–2.18, $I^2 = 24.32\%$) (Fig. 3). The positive mean difference indicates a statistically significant, greater improvement in SF-36 MCS scores with JAK inhibitors. Sensitivity analysis was performed by separately pooling the effect measure for JAK inhibitors vs. placebo, JAK inhibitors vs. any DMARD and JAK vs. adalimumab to assess the effect of JAK inhibitors in comparison with placebo/other DMARDs. Pooled incremental mean change in SF-36 MCS score for JAK monotherapy vs. placebo was 1.07 ($-0.28–2.43, I^2 = 37.24\%$) (Supplementary Fig. 9), indicating no statistically significant difference between JAK monotherapy and placebo. Pooled incremental mean change in SF-36 MCS score for JAK monotherapy vs. any...
DMARD and JAK vs. Adalimumab was 1.72 (0.84–2.59, $I^2 = 36.39\%$) and 1.04 (0.10–1.99, $I^2 = 0\%$) (Supplementary Figs. 10, 11), indicating significantly higher SF-36 MCS scores in patients treated with JAK monotherapy.

Pooled mean difference of incremental mean change in SF-36 MCS score with JAK combination therapy and placebo/DMARDs was obtained from four studies (Fig. 4). Pooled mean difference was 1.63 (0.52–2.75, $I^2 = 12.33\%$), showing that JAK inhibitors + MTX improves the mental health of RA patients better than placebo/DMARD. Publication bias was not assessed due to insufficient studies.

Sensitivity analysis was performed by separately pooling the effect measure for JAK + MTX vs. DMARD (Supplementary Fig. 12). Pooled incremental mean change of SF-36 MCS score was 1.45 (0.41–2.49, $I^2 = 0\%$), showing that JAK inhibitors + MTX are significantly effective than DMARDs in improving the mental health of RA patients. Meta-regression

Fig. 3 Forest plot showing the pooled mean difference of incremental mean change in mental health component of short form-36 questionnaire score between JAK inhibitors and other therapies for rheumatoid arthritis

Fig. 4 Forest plot showing the results of pooled mean difference of incremental mean change in mental health component of short form-36 questionnaire score between JAK combination therapy and placebo/DMARDs
analysis revealed that an improvement in MCS is associated with improvement in PCS following JAK treatment [coefficient = 0.093, (0.38–0.67), \( R^2 = 27.4 \), \( p = 0.009 \)] (Supplementary Fig. 13a). However, when meta-regression was performed for mean difference between the SF-36 MCS scores’ incremental mean change of JAK inhibitors therapy with that of other DMARDs/placebo, we observed that improvement in MCS was independent of PCS change [coefficient = 0.04 (–0.357–0.438), \( R^2 = 0 \), \( p = 0.84 \)] (Supplementary Fig. 13b).

**DISCUSSION**

We conducted a systematic review of RCTs to synthesize the effect of JAK inhibitors on the mental health of adult RA patients. With JAK inhibitors monotherapy, we observed a clinically noteworthy improvement in mental health from baseline in RA patients. Furthermore, when compared to other DMARDs/placebo, JAK inhibitors showed better improvement in mental health of RA patients. Among all the JAK inhibitors, tofacitinib showed a greater improvement in mental health followed by upadacitinib and baricitinib.

A 2018 systematic review that focused solely on the impact of biologic and targeted therapies of RA such as TNF-\( \alpha \), IL-6, and JAK inhibitors on mental health outcomes concluded that targeted biologic DMARDs showed similar effectiveness on mental health as conventional DMARDs [14]. However, the observations were not specific to JAK inhibitors. Meta-analysis indicates that JAK inhibitors surpassed conventional synthetic DMARDs and adalimumab in terms of improving mental health in RA patients. JAK inhibitors are effective in RA in part by inhibiting IL-6, a pleiotropic pro-inflammatory cytokine that contributes to synovial inflammation, articular joint destruction, and some of the systemic features seen in RA, according to the literature [45]. However, it is unclear whether improvements in mental health are due to bDMARDs directly influencing the inflammatory pathways or physical health improvements such as pain and disability reduction. When we meta-regressed the incremental mean change in MCS with SF-36 PCS scores in our meta-analysis, we found that improvement in MCS was independent of PCS but not statistically significant. Hence, evidence on whether JAK inhibitors could be beneficial in improving mental health regardless of whether patients respond clinically is inadequate. According to a network meta-analysis that compared the efficacy of tofacitinib, baricitinib, and upadacitinib, upadacitinib 15 mg once daily is the most effective in terms of ACR response and clinical remission for csDMARD-IR patients with RA [46]. The mechanism by which JAK inhibitors improve mental health, on the other hand, is not well understood. Currently available JAK inhibitors differ largely in their selectivity for distinct JAK receptors. Nonetheless, the selectivity that provides the best therapeutic impact while causing the least toxicity is unknown. Our findings indicate that tofacitinib, which targets JAK-3, improves SF-36 scores the most, speculating that JAK-3 inhibition may have the potential to alleviate depression symptoms in RA. However, there is a lack of evidence to substantiate this claim, which is beyond the scope of this review. Studies showed that stress activates JAK-3 in part through the acid sphingomyelinase, and inhibiting this enzyme reduces Jak-3 phosphorylation and improves hippocampal neurogenesis in mice [16]. However, a definitive conclusion cannot be reached in this regard because there appear to be no specific clinical trials that evaluated the therapeutic efficacy of JAK inhibitors for the treatment of depression in RA. Most of the RA clinical trials frequently use SF-36 to assess mental health. While this measure compares mental and physical QoL outcomes, it is important to note that the SF-36 MCS is a broader concept of HRQoL that is not limited to mental health. Despite the fact that the SF-36 assesses depression and anxiety, standard depression and anxiety scales may be required to find out the precise effect of JAK inhibitors on mental health. Therefore, future research on these newer RA treatments should focus on using specific tools to measure depression or anxiety.

Our meta-analysis included only phase 2 or 3 RCTs, indicating that included patients were
closely monitored for an extended period and patient-reported outcomes are frequently assessed. By quantifying responses with MCID values, clinically meaningful outcomes are obtained. The findings indicate that JAK inhibitor therapy improves mental health and overall HRQoL in patients with RA. These improvements in HRQoL associated with treatment are critical for patients and may aid policymakers in making decisions.

Several limitations are acknowledged. JAK inhibitors have been shown to improve HRQoL and symptoms in patients with RA who have failed to respond to first-line therapies such as MTX. This study analyzed SF-36 scores at baseline and at the most recent follow-up; data from other time points were not analyzed. Because of the lack of prior DMARD therapy stratification, the effect of JAK monotherapy on mental health outcomes could not be determined in few studies. Patients on placebo were switched to an intervention drug after 3 or 6 months in a few studies. Therefore, the effect of JAK inhibitors and placebo on mental health could not be compared at the maximum follow-up duration of these studies. The overall heterogeneity of the study could not be explained by subgroup analysis based on follow-up duration or clinical trial phase. Additional factors that contribute to overall heterogeneity must be identified. Certain studies were excluded because of our inability to obtain complete texts. While the funnel plot revealed no evidence of publication bias, it may be possible that insignificant mental health outcomes have been omitted.

**CONCLUSIONS**

In conclusion, JAK inhibitors therapy, both as monotherapy as well as in combination with MTX, results in a clinically relevant improvement in the mental health of the RA patients. More studies using specific measures to assess depression and anxiety outcomes are needed in the future to have a better insight of JAK inhibitors’ impact on the mental health of RA patients.

**Funding.** There was no specific funding for this work. Publication charges are met from Health Technology Assessment Resource Centre funds provided by Department of Health Research, New Delhi.

**Authorship.** All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

**Author Contributions.** Ghazala MH Shamail: Data curation, formal analysis, original draft. Madhumitha Haridoss: Conceptualization, data curation, formal analysis, inputs on original draft, review and editing. Meena Kumari: Data curation, review and editing. Vasna Joshua: Critical review and editing. Bhavani S Bagepally: Conceptualization, data curation, formal analysis, inputs on the original draft, methodology, software, critical review and editing.

**Disclosures.** Ghazala MH Shamail, Madhumitha Haridoss, Meena Kumari, Vasna Joshua, and Bhavani S Bagepally have nothing to disclose.

**Compliance with Ethics Guidelines.** This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

**Data Availability.** All data generated or analyzed during this study are included in this published article as supplementary information files.

**Open Access.** This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or
other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES

1. Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics. 2004;22:1–12.

2. Matcham F, Ali S, Irving K. Are depression and anxiety associated with disease activity in rheumatoid arthritis? A prospective study | BMC Musculoskeletal Disorders | Full Text. Available at: https://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/s12891-016-1011-1. Accessed 20 May 2021.

3. van den Hoek J, Boshuizen HC, Roorda LD, Tijhuis GJ, Nurmoshaimi MT, Dekker J, et al. Association of somatic comorbidities and comorbid depression with mortality in patients with rheumatoid arthritis: a 14-year prospective cohort study. Arthritis Care Res. 2016;68:1055–60.

4. Löwe B, Willand L, Eich W, Zipfel S, Ho AD, Herzog W, et al. Psychiatric comorbidity and work disability in patients with inflammatory rheumatic diseases. Psychosom Med. 2004;66:395–402.

5. Kojima M, Kojima T, Suzuki S, Oguchi T, Oba M, Tsuchiya H, et al. Depressive, inflammation, and pain in patients with rheumatoid arthritis. Arthritis Rheum. 2009;61:1018–24.

6. Matcham F, Ali S, Hotopf M, Chalder T. Psychological correlates of fatigue in rheumatoid arthritis: a systematic review. Clin Psychol Rev. 2015;39:16–29.

7. Matcham F, Rayner L, Steer S, Hotopf M. The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology. 2013;52:2136–48.

8. Tijhuis GJ, De Jong Z, Zwinderman AH. The validity of the Rheumatoid Arthritis Quality of Life (RAQoL) questionnaire - PubMed. Available at: https://pubmed.ncbi.nlm.nih.gov/11600740/. Accessed 7 June 2021.

9. Strand V, Singh JA. Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. Drugs. 2010;70:121–45.

10. Vallerand IA, Patten SB, Barnabe C. Depression and the risk of rheumatoid arthritis. Curr Opin Rheumatol. 2019;31:279–84.

11. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71:171–86.

12. Diffin JG, Lunt M, Marshall T, Chipping JR, Symmonds DPM, Verstappen SMM. Has the severity of rheumatoid arthritis at presentation diminished over time? J Rheumatol. 2014;41:1590–9.

13. Abbott R, Wheat R, Nikolaou V, Bethel A, Coon JT, Stein K, et al. Tumour necrosis factor-α inhibitor therapy in chronic physical illness: a systematic review and meta-analysis of the effect on depression and anxiety. J Psychosom Res. 2015;79:175–84.

14. Matcham F, Galloway J, Hotopf M, Roberts E, Scott IC, Steer S, et al. The impact of targeted rheumatoid arthritis pharmacologic treatment on mental health: a systematic review and network meta-analysis. Arthritis Rheumatol. 2018;70:1377–91.

15. Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O’Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;17:78.

16. Gulbins A, Grassmé H, Hoehn R, Kohnen M, Edwards M, Kornhuber J, et al. Role of Janus-kinases in major depressive disorder. Neurosignals. 2016;24:71–80.

17. Shariq AS, Brietzke E, Rosenblat JD, Pan Z, Rong C, Raggutt R-M, et al. Therapeutic potential of JAK/STAT pathway modulation in mood disorders. Rev Neurosci. 2019;30:1–7.

18. Genovese M, Westhovens R, Meuleners L, Van der Aa A, Harrison P, Tasset C, et al. Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes. Arthritis Res Ther. 2018;20:57.

19. Wallenstein GV, Kanik KS, Wilkinson B. Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials. Clin Exp Rheumatol. Available at: https://www.clinexpneumatol.org/abstract.asp?a=9525. Accessed 8 July 2021.
20. Strand V, Kremer J, Wallenstein G, Kanik KS, Connell C, Gruben D, et al. Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs. Arthritis Res Ther. 2015;17:307.

21. Strand V, Schiff M, Tundia N, Friedman A, Meerwein S, Pangan A, et al. Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs. Arthritis Res Ther. 2019;21:263.

22. Coombs JH, Bloom BJ, Breedveld FC, Fletcher MP, Gruben D, Kremer JM, et al. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2010;69:413–6.

23. Strand V, Mysler E, Moots RJ, Wallenstein GV, DeMasi R, Gruben D, et al. Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial. RMD Open. 2019;5:e001040.

24. Keystone EC, Taylor PC, Tanaka Y, Gaich C, DeLozier AM, Dudek A, et al. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab with methotrexate, in rheumatoid arthritis: secondary analyses from the RA-BEAM study. Ann Rheum Dis. 2017;76:1853–61.

25. Emery P, Blanco R, Maldonado Cocco J, Chen Y-C, Gaich CL, DeLozier AM, et al. Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis. RMD Open. 2017;3:e000410.

26. Smolen JS, Kremer JM, Gaich CL, DeLozier AM, Schlichting DE, Xie L, et al. Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). Ann Rheum Dis. 2017;76:694–700.

27. Schiff M, Takeuchi T, Fleischmann R, Gaich CL, DeLozier AM, Schlichting D, et al. Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Res Ther. 2017;19:208.

28. Yoshiya T, Makoto S, Hiroyuki N. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care & Research - Wiley Online Library 2011; Available at: https://onlinelibrary.wiley.com/doi/10.1002acr.20494. Accessed 8 July 2021.

29. Strand V, Van der DH, Tanaka Y. Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study. Clin Exp Rheumatol. Available at: https://www.clinexprrheumatol.org/abstract.asp?a=14326. Accessed 8 July 2021.

30. Strand V, Lee EB, Fleischmann R, Alten RE, Koncz T, Zwillich SH, et al. Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial. RMD Open. 2016;2:e000308.

31. Li Z, An Y, Su H, Li X, Xu J, Zheng Y, et al. Tofacitinib with conventional synthetic disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: patient-reported outcomes from a phase 3 randomized controlled trial. Int J Rheum Dis. 2018;21:402–14.

32. Strand V, Burmester GR, Zerbini CAF, Mebus CA, Zwillich SH, Gruben D, et al. Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: patient-reported outcomes from a phase III trial. Arthritis Care Res. 2015;67:475–83.

33. Yamanaka H, Tanaka Y, Takeuchi T, Sugiyama N, Yuasa H, Toyoizumi S, et al. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. Arthritis Res Ther. 2016;18:34.

34. Strand V, Pope J, Tundia N, Friedman A, Camp HS, Pangan A, et al. Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT. Arthritis Res Ther. 2019;21:272.

35. Strand V. Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY | Rheumatology | Oxford Academic. Available at: https://academic.oup.com/rheumatology/article/60/7/3209/6031466. Accessed 8 July 2021.

36. Alessandro L, Altman G D, Jeniffer T. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration | The BMJ. Available at: https://www.bmj.com/content/339/bmj.b2700. Accessed 2 June 2021.
37. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016;5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5139140/. Accessed 2 June 2021.

38. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.

39. Julian PT. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine. Wiley Online Library 2002; Available at: https://onlinelibrary.wiley.com/doi/abs/10.1002/sim.1186. Accessed 8 June 2021.

40. Jonathan JD, Julian PTH, Altman GD. 9 Analysing data and undertaking meta-analyses. Available at: https://handbook-5-1.cochrane.org/chapter_9/9_analysing_data_and_undertaking_meta_analyses.htm. Accessed 8 June 2021.

41. StataCorp. 2019. Stata | FAQ: Citing Stata software, documentation, and FAQs. Available at: https://www.stata.com/support/faqs/resources/citing-software-documentation-faq/. Accessed 2 June 2021.

42. Strand V, Boers M, Idzerda L, Kirwan JR, Kvien TK, Tugwell PS, et al. It’s good to feel better but it’s better to feel good and even better to feel good as soon as possible for as long as possible. Response criteria and the importance of change at OMERACT 10: figure 1. J Rheumatol. 2011;38:1720–7.

43. Egger M. Bias in meta-analysis detected by a simple, graphical test | The BMJ. Available at: https://www.bmj.com/content/315/7109/629. Accessed 8 June 2021.

44. Rendas-Baum R, Kosinski M, Singh A, Mebus CA, Wilkinson BE, Wallenstein GV. Estimated medical expenditure and risk of job loss among rheumatoid arthritis patients undergoing tofacitinib treatment: post hoc analyses of two randomized clinical trials. Rheumatology. 2017;56:1386–94.

45. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. 2011. https://doi.org/10.1056/NEJMra1004965. https://www.nejm.org/doi/10.1056/NEJMra1004965. Accessed 18 Nov 2021.

46. Pope J, Sawant R, Tundia N, Du EX, Qi CZ, Song Y, et al. Comparative efficacy of JAK inhibitors for moderate-to-severe rheumatoid arthritis: a network meta-analysis. Adv Ther. 2020;37:2356–72.